RxDoctor Payments Data

Kalli Karas, PA

Medical · Charlotte, NCNPI 1184394124

Payments from drug & device makers

$7,003in general payments, 2019–2025

Across 329 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Abbott$785
  • Boehringer Ingelheim$569
  • Boston Scientific$471
  • Novartis$462
  • Amgen$410
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$7,003100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,003 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$91,501
Medicare patients
951
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$224,520
EntrestoSacubitril/Valsartan67$77,738
JardianceEmpagliflozin54$66,617
XareltoRivaroxaban28$31,813
Repatha SureclickEvolocumab15$16,679
Repatha SyringeEvolocumab12$7,435
Rosuvastatin Calcium220$4,556
Diltiazem 24hr Er (Cd)Diltiazem Hcl102$4,186
Nebivolol Hcl68$3,521
Metoprolol Succinate251$3,190
Atorvastatin Calcium200$2,440
Ezetimibe67$1,349
Losartan Potassium107$1,327
Ranolazine ErRanolazine17$1,194
Valsartan32$1,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$224,520200 claims
NovartisEntresto$462$77,73867 claims
Boehringer IngelheimJardiance$569$66,61754 claims
Johnson & JohnsonXarelto$301$31,81328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.

Other medical in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →